1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68F96E0367F235C0D002585DC003E2642
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-evolving-patient-advocacy-relationships-support-programs-during-covid-19-pandemic?opendocument
18
19opendocument
2018.234.255.5
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Patient Focused Services Patient Advocacy Groups

Patient Support Excellence: Critical Programs, Tactics & Tools to Ensure Strong Advocacy & Access to Medicine during COVID-19 and Beyond

ID: 5636


Features:

6 Info Graphics

15 Data Graphics

260+ Metrics

7 Narratives


Pages/Slides: 30


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Support Excellence: Critical Programs, Tactics & Tools to Ensure Strong Advocacy & Access to Medicine during COVID-19 and Beyond”

In the wake of the COVID-19 pandemic, many organizations have poured more resources and attention into patient advocacy and support programs to boost their patient support.


Best Practices, LLC conducted this benchmarking research to understand critical patient advocacy and support trends that have arisen in response to COVID-19 and will drive patient support excellence in the future.

This study examines key support programs, tools, digital channels, communication frequency, performance measurement, staffing and other vital topics.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Agios; Alnylam Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; CSL Behring; Daiichi Sankyo; Genmab; Ironwood; Merck KGaA; Milestone Pharmaceuticals; MSD; Nestle Health Science; Novartis; OTSUKA; Pfizer; Retrophin; Sanofi; Takeda Pharmaceuticals; Theravance

Study Snapshot

Best Practices, LLC engaged 24 leaders at 20 biopharma companies in this research through a benchmarking survey. Nearly 60% of the participants serve at the Director / Head level or above.

Key topics covered in this study include:

  • Creative solutions for continuity of patient care
  • Implications of digital technology implementation
  • Evolvement and impact of patient assistance/support programs
  • Usage and effectiveness of performance metrics
  • Key patient support tools
  • Communication frequency and staffing
  • Post-pandemic changes to supporting advocacy groups

Key Findings

Select key insights uncovered from this research are noted below. Detailed findings are available in the full study.

  • Key patient support tools: Online FAQs provide answers to the most critical questions. Over 40% of companies who do not utilize this tool plan to do so in the next six weeks.
  • Advocacy group virtual engagement: Virtual platforms allow accessibility to online resources via support group sites and digital surveys for patients. There is a learning curve to using new technology platforms which may hamper present cross-collaboration.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.